Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock

Benzinga00:00

Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $28

Futu NewsNov 6 21:37 · Ratings

Oppenheimer Adjusts Entrada Therapeutics Price Target to $28 From $25, Maintains Outperform Rating

MT NewswiresNov 6 21:32 · Ratings

Entrada Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 6 20:46 · Ratings

Entrada Therapeutics Analyst Ratings

BenzingaNov 6 20:34 · Ratings

H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $20

Futu NewsNov 6 19:33 · Ratings